UB-VV111

N/A

Report date: 2026/04/23 20:00:25

Base Information

Drug NameUB-VV111
Drug Alias NameUB-VV111
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > In vivo CAR-T therapyCell and gene therapy > Cell therapy > In vivo cell therapy > In vivo CAR-T therapy
Mechanisms of ActionAnti-CD19T lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsHematologic NeoplasmsLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUmoja BioPharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie IncUmoja BioPharma Inc
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A